CO6592110A2 - Compuestos para suprimir un transtorno de los nervios perifericos inducidos por un agente anticanceigeno - Google Patents

Compuestos para suprimir un transtorno de los nervios perifericos inducidos por un agente anticanceigeno

Info

Publication number
CO6592110A2
CO6592110A2 CO12140288A CO12140288A CO6592110A2 CO 6592110 A2 CO6592110 A2 CO 6592110A2 CO 12140288 A CO12140288 A CO 12140288A CO 12140288 A CO12140288 A CO 12140288A CO 6592110 A2 CO6592110 A2 CO 6592110A2
Authority
CO
Colombia
Prior art keywords
disorder
suppressing
compounds
anticancer agent
peripheral nerves
Prior art date
Application number
CO12140288A
Other languages
English (en)
Spanish (es)
Inventor
Naomi Kitamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6592110(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6592110A2 publication Critical patent/CO6592110A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO12140288A 2010-01-27 2012-08-17 Compuestos para suprimir un transtorno de los nervios perifericos inducidos por un agente anticanceigeno CO6592110A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27

Publications (1)

Publication Number Publication Date
CO6592110A2 true CO6592110A2 (es) 2013-01-02

Family

ID=43770309

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12140288A CO6592110A2 (es) 2010-01-27 2012-08-17 Compuestos para suprimir un transtorno de los nervios perifericos inducidos por un agente anticanceigeno

Country Status (41)

Country Link
US (5) US20130046000A1 (cg-RX-API-DMAC7.html)
EP (1) EP2528598B1 (cg-RX-API-DMAC7.html)
JP (2) JP6131046B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120118044A (cg-RX-API-DMAC7.html)
CN (2) CN102821763B (cg-RX-API-DMAC7.html)
AR (1) AR080024A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011211294B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018434A2 (cg-RX-API-DMAC7.html)
CA (1) CA2788150C (cg-RX-API-DMAC7.html)
CL (1) CL2012002079A1 (cg-RX-API-DMAC7.html)
CO (1) CO6592110A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120412A (cg-RX-API-DMAC7.html)
CY (1) CY1117268T1 (cg-RX-API-DMAC7.html)
DK (1) DK2528598T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000209A (cg-RX-API-DMAC7.html)
EA (1) EA201290697A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012126A (cg-RX-API-DMAC7.html)
ES (1) ES2560215T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166441B (cg-RX-API-DMAC7.html)
HR (1) HRP20160165T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027310T2 (cg-RX-API-DMAC7.html)
IL (1) IL221066A (cg-RX-API-DMAC7.html)
MA (1) MA34014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02364B (cg-RX-API-DMAC7.html)
MX (1) MX2012008514A (cg-RX-API-DMAC7.html)
MY (1) MY163936A (cg-RX-API-DMAC7.html)
NZ (1) NZ601635A (cg-RX-API-DMAC7.html)
PE (1) PE20121694A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501538A1 (cg-RX-API-DMAC7.html)
PL (1) PL2528598T3 (cg-RX-API-DMAC7.html)
PT (1) PT2528598E (cg-RX-API-DMAC7.html)
RS (1) RS54591B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201503402XA (cg-RX-API-DMAC7.html)
SI (1) SI2528598T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600103B (cg-RX-API-DMAC7.html)
TN (1) TN2012000364A1 (cg-RX-API-DMAC7.html)
TW (1) TWI481401B (cg-RX-API-DMAC7.html)
UA (1) UA109540C2 (cg-RX-API-DMAC7.html)
UY (1) UY33203A (cg-RX-API-DMAC7.html)
WO (1) WO2011093512A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205681B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428477B2 (en) * 2012-04-27 2016-08-30 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
CN105934253A (zh) * 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
JP6718884B2 (ja) 2015-05-08 2020-07-08 武田薬品工業株式会社 環状化合物
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2019047812A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0252146B1 (en) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0407411B1 (en) 1988-03-01 1993-11-10 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0465565B1 (en) 1989-03-31 1996-05-15 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
WO1992003137A1 (en) 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ATE182076T1 (de) 1991-04-19 1999-07-15 Childrens Medical Center Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
MX9709442A (es) * 1995-06-07 1998-02-28 Sugen Inc Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ATE381574T1 (de) 1997-10-17 2008-01-15 Genentech Inc Menschliche toll-homologe
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
AU1539399A (en) 1997-11-25 1999-06-15 Medical University Of South Carolina Inhibitors of nitric oxide synthase
EP1063228B1 (en) 1998-03-09 2005-01-19 Takeda Pharmaceutical Company Limited Cycloalkene derivatives, process for producing the same, and use
DE60045033D1 (de) 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
AU6488901A (en) 2000-05-25 2001-12-03 Schering Corp Human receptor proteins; related reagents and methods
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
DE60144570D1 (de) 2000-10-18 2011-06-16 Takeda Pharmaceutical Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese
JP4498678B2 (ja) 2000-11-30 2010-07-07 株式会社トクヤマ 基板およびその製造方法
AU2002221099A1 (en) 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP5137289B2 (ja) 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
WO2003084527A1 (en) 2002-04-08 2003-10-16 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2004074435A2 (en) 2003-01-30 2004-09-02 Emory University Methods for identifying and administering agents that bias the immune response via dendritic cells
WO2004075865A2 (en) 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
JP2006523452A (ja) 2003-03-25 2006-10-19 スリーエム イノベイティブ プロパティズ カンパニー 共通のＴｏｌｌ様受容体を通じて媒介される細胞活性の選択的活性化
JP2007505629A (ja) 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
TWI462745B (zh) 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
BRPI0611079A2 (pt) 2005-06-03 2010-08-03 Ono Pharmaceutical Co agentes para a regeneração e/ou proteção de nervos
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
US20090175835A1 (en) 2006-02-07 2009-07-09 Korea Institute Of Radiological & Medical Sciences Composition for treating damage of central or peripheral nerve system
US7985538B2 (en) 2006-02-23 2011-07-26 Yale University Drug resistance and methods of reversing
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2007114296A1 (ja) 2006-03-30 2007-10-11 Hiroshima University スクリーニング方法
WO2007123186A1 (ja) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
JPWO2007132825A1 (ja) 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20090209585A1 (en) 2006-07-07 2009-08-20 Takashi Ichikawa Cycloalkene derivatives, process for production of the derivatives, and use of the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
WO2009145814A2 (en) 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
CA2774008C (en) 2009-09-23 2017-06-20 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof

Also Published As

Publication number Publication date
TN2012000364A1 (en) 2014-01-30
KR20120118044A (ko) 2012-10-25
ME02364B (me) 2016-06-20
AR080024A1 (es) 2012-03-07
ECSP12012126A (es) 2012-09-28
ES2560215T3 (es) 2016-02-17
GEP20166441B (en) 2016-03-10
SMT201600103B (it) 2016-04-29
CL2012002079A1 (es) 2012-12-21
CR20120412A (es) 2012-11-13
UA109540C2 (uk) 2015-09-10
JP2016175903A (ja) 2016-10-06
WO2011093512A1 (en) 2011-08-04
US20160166526A1 (en) 2016-06-16
DK2528598T3 (en) 2016-03-07
PT2528598E (pt) 2016-03-04
BR112012018434A2 (pt) 2016-04-19
SI2528598T1 (sl) 2016-04-29
JP6131046B2 (ja) 2017-05-17
CN102821763B (zh) 2017-09-22
US20150203464A1 (en) 2015-07-23
JP2013518032A (ja) 2013-05-20
AU2011211294A1 (en) 2012-09-20
RS54591B1 (sr) 2016-08-31
TW201130482A (en) 2011-09-16
EP2528598B1 (en) 2016-01-13
MY163936A (en) 2017-11-15
EP2528598A1 (en) 2012-12-05
AU2011211294B2 (en) 2014-11-13
CN104744321A (zh) 2015-07-01
US8901171B2 (en) 2014-12-02
SG182522A1 (en) 2012-08-30
CA2788150A1 (en) 2011-08-04
SG10201503402XA (en) 2015-06-29
US20130046000A1 (en) 2013-02-21
PL2528598T3 (pl) 2016-06-30
US20150051256A1 (en) 2015-02-19
TWI481401B (zh) 2015-04-21
US20130345304A1 (en) 2013-12-26
PE20121694A1 (es) 2012-12-06
MA34014B1 (fr) 2013-02-01
IL221066A (en) 2016-10-31
UY33203A (es) 2011-08-31
HUE027310T2 (en) 2016-10-28
CA2788150C (en) 2017-06-06
HRP20160165T1 (hr) 2016-03-11
CN102821763A (zh) 2012-12-12
PH12012501538A1 (en) 2015-11-09
CY1117268T1 (el) 2017-04-26
NZ601635A (en) 2013-06-28
AU2011211294A2 (en) 2012-10-04
HK1177423A1 (zh) 2013-08-23
EA201290697A1 (ru) 2013-02-28
ZA201205681B (en) 2013-09-25
DOP2012000209A (es) 2012-12-31
MX2012008514A (es) 2012-08-17

Similar Documents

Publication Publication Date Title
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
MX2015012644A (es) Tratamiento de cataplejia.
CO6592110A2 (es) Compuestos para suprimir un transtorno de los nervios perifericos inducidos por un agente anticanceigeno
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
CR20150364A (es) Compuesto heterociclico
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
EA033555B1 (ru) Фармацевтические композиции для лечения серповидно-клеточного нарушения
BR112015027951A2 (pt) arilquinazolinas
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
CO7101239A2 (es) Composiciones derivadas de la quitosana
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
PH12021550360A1 (en) Treatment of brain cancer
SV2017005429A (es) Alcoholes de trifluorometilo como moduladores de roryt
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.

Legal Events

Date Code Title Description
FC Application refused